Sept 19 (Reuters) – Japan’s Astellas Pharma Inc and
San Diego-based Vical Inc said their experimental
herpes vaccine failed a mid-stage study involving certain kidney
transplant patients.
The post Astellas, Vical herpes vaccine fails mid-stage study appeared first on NASDAQ.